Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06726304
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
01
Overview
PF-06726304 is a small molecule inhibitor of the Polycomb Repressive Complex 2 (PRC2), specifically targeting the catalytic subunit Enhancer of Zeste Homolog 2 (EZH2) and the regulatory subunit Embryonic Ectoderm Development (EED). Developed by Pfizer, it is primarily investigated for its activity against malignant melanoma. Unlike traditional EZH2 inhibitors that primarily block histone H3K27 trimethylation, PF-06726304 has been observed to markedly reduce the protein levels of EED and EZH2 without significantly altering total H3K27me3 levels in certain cell lines. Its anti-tumor mechanism is also linked to the modulation of the Akt-EZH2 signaling axis, characterized by reduced phosphorylation of Akt (Ser473) and EZH2 (Ser21).
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)EED (Embryonic ectoderm development protein)
Beyond the preview
Go deeper on PF-06726304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06726304.